Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis

Table 5

Correlation between clinical data and laboratory parameters.

Stage	Clinical characteristics		OX40 on CD4^+ cells (%)	OX40L on CD19^+ cells (%)	OX40L on CD14^+ cells (%)	sOX40 (ng/ml)	sOX40L (ng/ml)
	Age (years)		-0.018	0.074	0.063	0.090	-0.156
			0.915	0.654	0.702	0.596	0.357
			39	39	39	37	37
	QMGs		0.032	-0.031	0.036	0.126	-0.119
			0.846	0.851	0.829	0.459	0.483
			39	39	39	37	37
Baseline	AchR-Ab (nmol/L)		0.152	-0.024	0.015	-0.178	-0.241
			0.354	0.884	0.928	0.292	0.150
			39	39	39	37	37
	Disease duration (months)		-0.215	-0.258	-0.035	-0.050	-0.032
			0.188	0.127	0.831	0.770	0.849
			39	39	39	37	37
	Age (years)		-0.095	-0.091	0.066	0.110	-0.153
			0.552	0.569	0.679	0.563	0.419
			42	42	42	30	30
	QMGs		0.156	-0.008	-0.148	0.104	0.255
			0.324	0.962	0.350	0.583	0.173
			42	42	42	30	30
Remission	AchR-AR (nmol/L)		-0.008	-0.008	-0.050	-0.181	-0.049
			0.964	0.959	0.771	0.339	0.799
			37		37	30	30
	Disease duration (months)		0.112	-0.008	-0.107	-0.004	-0.095
			0.482	0.959	0.498	0.983	0.618
			42	42	42	30	30
	Age (years)		-0.356	-0.316	-0.339	0.151	0.101
			0.103	0.152	0.123	0.394	0.954
			22	22	22	34	34
	QMGs		0.213	0.155	0.281	0.070	-0.129
			0.342	0.491	0.205	0.693	0.467
			22	22	22	34	34
Relapse	AchR-AR (nmol/L)		0.485	0.102	0.226	0.048	-0.051
			0.022	0.653	0.311	0.790	0.772
			22	22	22	34	34
	Disease duration (months)		-0.001	-0.650	-0.423	0.204	0.224
			0.998	0.001	0.050	0.248	0.202
			22	22	22	34	34